Leaflet: information for the user
Solifenacin VIR 5 mg film-coated tablets EFG
Solifenacin, succinate
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
1. What isSolifenacin Virand what it is used for
2. What you need to know before starting to takeSolifenacin Vir
3. How to takeSolifenacin Vir
4. Possible side effects
5. Storage ofSolifenacin Vir
6. Contents of the pack and additional information
The active ingredient of SolifenacinaVirbelongs to the group of anticholinergics. These medications are used to reduce the activity of an overactive bladder. This allows you to have more time before needing to go to the bathroom and increases the amount of urine that your bladder can hold.
SolifenacinaViris used to treat the symptoms of overactive bladder syndrome. These symptoms include: having a strong and sudden need to urinate without prior warning, having to urinate frequently or having urine leaks due to not making it to the bathroom in time.
Do not take SolifenacinaVir
- if you are allergic to solifenacin succinate or any of the other ingredients of this
medication (listed in section 6),
- if you have difficulty urinating or emptying your bladder completely (urinary retention),
- if you have a severe stomach or intestinal disorder (including toxic megacolon, a
complication associated with ulcerative colitis),
- if you have a muscle disease called myasthenia gravis, which can cause extreme weakness
in certain muscles,
- if you have high eye pressure with gradual loss of vision (glaucoma),
- if you are undergoing renal dialysis,
- if you have severe liver disease,
- if you have severe kidney disease or moderate liver disease and are being treated with
medications that can decrease the elimination of solifenacin from the body (e.g. ketoconazole).
Your doctor or pharmacist will inform you if this is the case.
Before starting treatment with solifenacin, inform your doctor if you have or have had any of the above-mentioned diseases.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
- if you have difficulty emptying your bladder (bladder obstruction) or urinating (e.g. a weak
urine flow). The risk of urine accumulation in the bladder (urinary retention) is much
higher,
- if you have any obstruction of the digestive system (constipation),
- if you have an increased risk of decreased digestive system activity (gastrointestinal
motility). Your doctor will inform you if this is the case,
- if you have severe kidney disease,
- if you have moderate liver disease,
- if you have hiatal hernia or heartburn,
- if you have a nervous system disorder (autonomic neuropathy).
Children and adolescents
This medication should not be used in children or adolescents under 18 years of age.
Inform your doctor before starting treatment with this medication, if any of the above-mentioned circumstances have occurred at any time.
Before starting treatment with solifenacin, your doctor will evaluate whether there are other causes for your need to urinate frequently (e.g. heart failure or kidney disease). If you have a urinary tract infection, your doctor will prescribe an antibiotic (a treatment for certain bacterial infections).
Use of SolifenacinaVirwith other medications
Inform your doctor or pharmacist that you are using, have used recently or may need to use any other medication.
It is especially important to inform your doctor if you are taking:
- other anticholinergic medications, the activity and adverse effects of both
medications may increase,
- cholinergic medications as they may reduce the effect of solifenacin,
- medications such as metoclopramide or cisapride, which make the digestive system
work faster. Solifenacin may reduce its effect,
- medications such as ketoconazole, ritonavir, nelfinavir, itraconazole, verapamil and
diltiazem, which decrease the elimination of solifenacin from the body,
- medications such as rifampicin, phenytoin and carbamazepine, which may increase the
elimination of solifenacin from the body,
- medications such as bisphosphonates, which may cause or worsen esophagitis.
Use of SolifenacinaVirwith food, drinks and alcohol
This medication can be taken with or without food, as you prefer.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
You should not use solifenacin if you are pregnant unless absolutely necessary.
Do not use solifenacin during breastfeeding as solifenacin may pass into breast milk.
Driving and operating machinery
Solifenacin may cause blurred vision and sometimes drowsiness or fatigue. If you experience any of these side effects, do not drive or operate machinery.
SolifenacinaVircontains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Instructions for Correct Use
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Swallow the entire tablet with some liquid. You can take it with or without food, as you prefer. Do not crush the tablets.
The recommended dose is 5 mg per day, unless your doctor tells you to take 10 mg per day.
If You Take More SolifenacinaVirThan You Should
In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
The symptoms of an overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not there (hallucinations), pronounced excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), urine accumulation in the bladder (urinary retention), and dilation of the pupils (mydriasis).
If You Forget to Take SolifenacinaVir
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take the next dose. Never take more than one dose per day. If you have any doubts, consult your doctor or pharmacist always.
If You Interrupt Treatment with SolifenacinaVir
If you stop taking solifenacina, your overactive bladder symptoms may return or worsen. Consult your doctor always if you are thinking of interrupting treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you experience an allergic attack or a severe skin reaction (for example, blistering and peeling of the skin), you must inform your doctor or nurse immediately.
Angioedema (allergy on the skin resulting in inflammation that occurs in the tissue beneath the skin surface) with respiratory tract obstruction (difficulty breathing) has been reported in some patients treated with solifenacin succinate.
If angioedema appears, treatment with solifenacin succinate must be stopped immediatelyand appropriate treatment and/or measures must be taken.
Solifenacin may cause the following side effects:
Very common (may affect more than 1 in 10 people)
- Dry mouth,
Common (may affect up to 1 in 10 people)
- Blurred vision,
- Constipation, nausea, indigestion with symptoms such as a feeling of stomach heaviness, abdominal pain, belching, nausea, and stomach burning (dyspepsia), stomach discomfort.
Rare side effects (may affect up to 1 in 100 people)
- Urinary tract infection, bladder infection,
- Drowsiness,
- Abnormal taste perception (dysgeusia),
- Dry, irritated eyes,
- Nasal dryness,
- Gastroesophageal reflux disease (GERD),
- Dry throat,
- Dry skin,
- Difficulty urinating,
- Fatigue,
- Swelling of the lower extremities (edema).
Rare side effects (may affect up to 1 in 1,000 people)
- Accumulation of a large amount of hardened feces in the large intestine (fecal impaction),
- Urine accumulation in the bladder due to inability to empty the bladder (urinary retention),
- Dizziness, headache,
- Vomiting,
- Itching, skin rash.
Very rare side effects (may affect up to 1 in 10,000 people)
- Hallucinations, confusion,
- Allergic skin rash.
Unknown frequency (frequency cannot be estimated from available data)
- Decreased appetite, high potassium levels in the blood that may cause an abnormal heart rhythm,
- Increased eye pressure,
- Changes in heart electrical activity (ECG), irregular heartbeats (Torsades de Pointes),
- Voice disorder,
- Liver disorder,
- Muscle weakness,
- Kidney disorder.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use Website:www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of SolifenacinaVir
- The active ingredient is solifenacina succinate 5 mg (equivalent to 3.8 mg of solifenacina).
- The other components (excipients) are:
Tablet core: Lactose monohydrate, Cornstarch, Pregelatinized cornstarch, and Magnesium stearate.
Coating: Opadry Yellow: Hypromellose (E464), Titanium dioxide (E171), Macrogol 8000, Talc, , Yellow iron oxide (E172) .
Appearance of the product and content of the packaging
Solifenacina Vir 5 mg coated tablets are round, biconvex, yellowish-colored tablets.
Solifenacina Vir tablets are supplied in blisters of 30 tablets.
Marketing authorization holder
Industria Química y Farmacéutica VIR, S.A.
C/ Laguna 66-70, Polígono Industrial URTINSA II
28923 Alcorcón (Madrid)
Spain
Responsible for manufacturing
Genepharm S.A.
18 km Marathon Avenue,
153 51 Pallini Attikis
Greece
Last review date of this leaflet:December 2016
The detailed and updated information of this medication is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)
http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.